We are live on ! Find out more
BKYI

BIO-key International
BKYI

11 hedge funds and large institutions have $115K invested in BIO-key International in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

10% more funds holding

Funds holding: 10 → 11 (+1)

1.18% less ownership

Funds ownership: 1.4% → 0.22% (-1.2%)

57% less capital invested

Capital invested by funds: $265K → $115K (-$151K)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$19.8K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$10.9K
3
XT
XTX Topco
Cayman Islands
+$9.94K
4
Citigroup
Citigroup
New York
+$2.48K
5
TRCT
Tower Research Capital (TRC)
New York
+$1.65K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$240K
2
UBS Group
UBS Group
Switzerland
-$6.05K
3
Wells Fargo
Wells Fargo
California
-$39
4
HT
Headlands Technologies
Illinois
-$15

BKYI Hedge Fund Activity: Q4 2024 in Review

11 of the 7,519 institutional investors tracked by Wall St. Rank reported a position in BIO-key International (BKYI) for Q4 2024, worth a combined $115K — down 57% from $265K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BKYI positions and 4 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $240K sold.

  • 11 institutional investors held BIO-key International (BKYI) as of Q4 2024, up from 10 in Q3 2024.
  • Funds reported $115K of BIO-key International stock for Q4 2024, down 57% quarter-over-quarter.
  • 5 funds opened new BIO-key International positions in Q4 2024 and 4 closed out, a net change of +1 holder.
  • The largest BIO-key International buyer in Q4 2024 was Citadel Advisors, an estimated $19.8K added.
  • The largest BIO-key International seller in Q4 2024 was Armistice Capital, an estimated $240K sold.

Based on aggregated 13F filings for Q4 2024.